Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of CRd in Transplant Candidates With Newly Diagnosed Multiple Myeloma
NCT01816971Phase 2Completed
- Sponsor
- University of Chicago
- Start
- Jan 2013
- Primary completion
- Apr 2018
- Modality
- Reversible Covalent Inhibitors, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of carfilzomib, lenalidomide and dexamethasone in multiple myeloma (MM), sponsored by University of Chicago. Primary endpoint: Stringent Complete Response at Day 224. Started Jan 2013; status: completed.
02
Drugs
carfilzomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01816971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01816971.